Merck Serono and Quintiles Announce Innovative Clinical Development Partnership

  Merck Serono and Quintiles Announce Innovative Clinical Development

Agreement Creates Unique Strategic Collaboration for Development and Clinical
                               Trial Execution

Business Wire


Merck Serono, a division of Merck, Darmstadt, Germany, and Quintiles, the
world’s largest provider of biopharmaceutical development and commercial
outsourcing services, today announced a new, five-year clinical development
agreement. This strategic collaboration is the first-of-its-kind between a
biopharmaceutical company and a biopharmaceutical services provider, creating
a comprehensive process that integrates the expertise and experience from both
organizations into a single, well-aligned clinical development engine.

In a novel approach to clinical development that is founded on a shared
commitment to cost-disciplined science, the collaboration is intended to
optimize productivity in the design and execution of studies with a focus on
quality, speed and efficiency.

Under this agreement, Merck Serono will shape and lead the strategy of its
clinical development programs, with Quintiles directing clinical trial
planning and execution. Quintiles also will be a key contributor to Merck
Serono’s future clinical trial design activities. In this capacity, Quintiles
will focus on delivering superior performance based on optimized clinical
trial design and execution strategies, using highly efficient processes and
proven technologies.

To fully leverage the expertise of both organizations, leaders from Quintiles
will collaborate in strategic decision-making processes affecting the
development of the Merck Serono portfolio.

“By combining the strengths of Merck Serono and Quintiles, we are creating a
new model in clinical development that will unlock the knowledge and insights
of both companies,” says Annalisa Jenkins, Executive Vice President and Head
of Global Development and Medical at Merck Serono. “This is an innovative and
unique collaboration that will help to translate the highest-quality science
into efficiency and agility throughout our clinical trials, while enhancing
our competitive position in an increasingly challenging environment of
clinical drug development.”

Moving forward, Quintiles will be the sole primary provider of Merck Serono’s
outsourced clinical development services for its global clinical programs. The
agreement will span the full spectrum of clinical development, from Phase I
through to post-marketing approvals. Importantly, it will also allow Merck
Serono to expand its reach globally by leveraging the broad local expertise of
Quintiles to implement development programs around the world.

“This agreement is built upon a long-standing commitment to trust and
transparency between our two organizations, and I’m confident it will only be
enhanced by this innovative relationship,” says Tom Pike, Chief Executive
Officer, Quintiles. “We are excited about the opportunities this collaboration
provides as we work with Merck Serono in a new and innovative manner that
leverages the best of our combined capabilities. We view this as a key step
forward not only for our two companies, but for the way the industry
approaches the development of new therapies for the patients we ultimately

The agreement reflects a shared commitment between both organizations to
delivering optimal performance in clinical development. The objective is to
expedite the delivery of new therapeutic options to patients with high medical
need across Merck Serono’s core research therapeutic areas of neurology,
oncology, immuno-oncology and immunology.

About Quintiles

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical
development and commercial outsourcing services with a network of more than
27,000 employees conducting business in approximately 100 countries.We have
helped develop or commercialize all of the top-50 best-selling drugs on the
market. Quintiles applies the breadth and depth of our service offerings along
with extensive therapeutic, scientific and analytics expertise to help our
customers navigate an increasingly complex healthcare environment as they seek
to improve efficiency and effectiveness in the delivery of better healthcare

About Merck Serono

Merck Serono is the biopharmaceutical division of Merck. With headquarters in
Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to
help patients with cancer, multiple sclerosis, infertility, endocrine and
metabolic disorders as well as cardiovascular diseases. In the United States
and Canada, EMD Serono operates as a separately incorporated subsidiary of
Merck Serono.

Merck Serono discovers, develops, manufactures and markets prescription
medicines of both chemical and biological origin in specialist indications. We
have an enduring commitment to deliver novel therapies in our core focus areas
of neurology, oncology, immuno-oncology and immunology.

About Merck

Merck is a leading pharmaceutical, chemical and life science company with
total revenues of €11.2 billion in 2012, a history that began in 1668, and a
future shaped by approx. 39,000 employees in 66 countries. Its success is
characterized by innovations from entrepreneurial employees. Merck's operating
activities come under the umbrella of Merck KGaA, in which the Merck family
holds an approximately 70% interest and free shareholders own the remaining
approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated
and has been an independent company ever since.

For more information, please visit or

This press release may contain forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such forward-looking statements reflect, among other
things, Quintiles’ current expectations and anticipated results of operations,
all of which are subject to known and unknown risks, uncertainties and other
factors that may cause Quintiles’ actual results, performance or achievements,
market trends, or industry results to differ materially from those expressed
or implied by such forward-looking statements. Therefore, any statements
contained herein that are not statements of historical fact may be
forward-looking statements and should be evaluated as such. Without limiting
the foregoing, the words “anticipates,” “believes,” “estimates,” “expects,”
“intends,” “may,” “plans,” “projects,” “should,” “targets,” “will” and the
negative thereof and similar words and expressions are intended to identify
forward-looking statements. These statements are subject to risks,
uncertainties and assumptions, including those described under the section
entitled "Risk Factors" in Quintiles’ prospectus dated May 8, 2013, filed with
the SEC pursuant to Rule 424(b) of the Securities Act on May 9, 2013, as such
factors may be updated from time to time in Quintiles’ periodic filings with
the SEC, which are accessible on the SEC's website at These
factors should not be construed as exhaustive and should be read in
conjunction with the other cautionary statements that are included in this
release and in Quintiles’ filings with the SEC. Unless legally required,
Quintiles assumes no obligation to update any such forward-looking information
to reflect actual results or changes in the factors affecting such
forward-looking information.

Click here to subscribe to Mobile Alerts for Quintiles.


Kevin Nash, Media Relations, +1 919-998-2514
Karl Deonanan, Investor Relations, +1 919-998-2789
Press spacebar to pause and continue. Press esc to stop.